Picture of Synairgen logo

SNG — Synairgen Share Price

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock

Momentum

Relative Strength (%)
1m+21.92%
3m+45.79%
6m-84.35%
1yr-81.9%
Volume Change (%)
10d/3m-73.1%
Price vs... (%)
52w High-86.6%
50d MA+9.02%
200d MA-73.38%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-156.39%
Return on Equity-79.68%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for SNG

Could Synairgen (LON:SNG) be a turtle trade? background image

Could Synairgen (LON:SNG) be a turtle trade?

Ever since the 1980s, when the now-infamous "Turtle Traders" beat the market with simple strategies based on breakouts to new high prices, momentum investing has been shown to be a potentially profitable strategy.  In fact, many academ...

Will the Synairgen (LON:SNG) share price keep rising? background image

Will the Synairgen (LON:SNG) share price keep rising?

Despite general economic uncertainty, shares in Synairgen (LON:SNG) have been in an uptrend in recent months. The question now for investors is whether that price strength will continue. Finding stocks with the potential to break-out a...

As Synairgen hits a yearly high, is it too late to buy shares? background image

As Synairgen hits a yearly high, is it too late to buy shares?

With shares in Synairgen (LON:SNG) currently trading close to a 52 week high, a question many on the sidelines probably have is: "was I too late to buy them"? The share price is up by around 27.8% over the past week. On a one-month bas...

Will the Synairgen (LON:SNG) share price keep rising? background image

Will the Synairgen (LON:SNG) share price keep rising?

Despite the market volatility, shares in Synairgen (LON:SNG) have been in an uptrend in recent months. The question now for investors is whether that price strength will continue. Finding stocks with the potential to break-out as their...

Which way is the Synairgen share price trending? background image

Which way is the Synairgen share price trending?

Despite economic uncertainty and market volatility, shares in Synairgen (LON:SNG) have been in an uptrend in recent months. The question now for investors is whether that price strength will continue. Finding stocks with the potential...

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Synairgen EPS forecast chart

Profile Summary

Synairgen plc is a drug discovery and development company. The Company’s primary focus is developing SNG001 (inhaled interferon beta) for the treatment of coronavirus disease (COVID-19) as potentially the host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs. The Company is also engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma chronic obstructive pulmonary disease (COPD). The Company is developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta for the treatment of severe viral lung infections. The Company offers a range of products, including Cablivi, Orthoclone OKT3, Remicade and ReoPro. The Company uses its human biology BioBank platform to discover and develop therapies for respiratory disease. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models.

Directors

Last Annual
December 31st, 2021
Last Interim
December 31st, 2021
Incorporated
September 16th, 2004
Public Since
October 26th, 2004
No. of Employees
24
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
gb flag iconLondon Stock Exchange
Shares in Issue
201,341,825

SNG Share Price Performance

Latest News for SNG

Upcoming Events for SNG

Half Year 2022 Synairgen PLC Earnings Release

Similar to SNG

Picture of 4Basebio logo

4Basebio

gb flag iconLondon Stock Exchange

Picture of 4d Pharma logo

4d Pharma

gb flag iconLondon Stock Exchange

Picture of Allergy Therapeutics logo

Allergy Therapeutics

gb flag iconLondon Stock Exchange

Picture of Arecor Therapeutics logo

Arecor Therapeutics

gb flag iconLondon Stock Exchange

Picture of Avacta logo

Avacta

gb flag iconLondon Stock Exchange

FAQ

Or unlock with your email

Or unlock with your email